Drugs / ASP2408
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02140125 | Aug 2012 → Oct 2013 | — | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 1 | NCT02052375 | Jun 2012 → Dec 2013 | rheumatoid arthritis | Astellas Pharma Global Development, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02150070 | Aug 2011 → Jun 2012 | — | Astellas Pharma Global Development, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02125435 | Jan 2011 → May 2012 | — | Astellas Pharma Global Development, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASP2408 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02150070 ↗ |
| Route | Subcutaneous | “subcutaneous injection” NCT02052375 ↗ |